Literature DB >> 18194660

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

Ding Wu1, Michael R Mand, Darren R Veach, Laurie L Parker, Bayard Clarkson, Stephen J Kron.   

Abstract

Regulated phosphorylation by protein tyrosine kinases (PTKs), such as c-Abl, is critical to cellular homeostasis. In turn, once deregulated as in the chronic myeloid leukemia (CML) fusion protein Bcr-Abl, PTKs can promote cancer onset and progression. The dramatic success of the Bcr-Abl inhibitor imatinib as therapy for CML has inspired interest in other PTKs as targets for cancer drug discovery. Here we report a novel PTK activity and inhibition screening method using hydrogel-immobilized peptide substrates. Using acrylate crosslinkers, we tether peptides via terminal cysteines to thiol-presenting hydrogels in 96-well plates. These surfaces display low background and high reproducibility, allowing semiquantitative detection of peptide phosphorylation by recombinant c-Abl or by Bcr-Abl activity in cell extracts using traditional anti-phosphotyrosine immunodetection and chemifluorescence. The capabilities of this assay are demonstrated by performing model screens for inhibition with several commercially available PTK inhibitors and a collection of pyridopyrimidine Src/Abl dual inhibitors. This assay provides a practical method to measure the activity of a single kinase present in a whole cell lysate with high sensitivity and specificity as a valuable means for efficient small molecule screening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18194660      PMCID: PMC2291073          DOI: 10.1016/j.ab.2007.12.023

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  46 in total

1.  Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

Authors:  X Sun; J E Layton; A Elefanty; G J Lieschke
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

2.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

3.  Peptide and small molecule microarray for high throughput cell adhesion and functional assays.

Authors:  J R Falsey; M Renil; S Park; S Li; K S Lam
Journal:  Bioconjug Chem       Date:  2001 May-Jun       Impact factor: 4.774

4.  Peptide and small-molecule microarrays.

Authors:  Jan Marik; Kit S Lam
Journal:  Methods Mol Biol       Date:  2005

Review 5.  Overcoming drug resistance in chronic myeloid leukemia.

Authors:  Jorge Cortes
Journal:  Curr Opin Hematol       Date:  2006-03       Impact factor: 3.284

6.  Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.

Authors:  S Trumpp-Kallmeyer; J R Rubin; C Humblet; J M Hamby; H D Showalter
Journal:  J Med Chem       Date:  1998-05-21       Impact factor: 7.446

7.  New tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  Giovanni Martinelli; Simona Soverini; Gianantonio Rosti; Daniela Cilloni; Michele Baccarani
Journal:  Haematologica       Date:  2005-04       Impact factor: 9.941

8.  Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

Authors:  J M Hamby; C J Connolly; M C Schroeder; R T Winters; H D Showalter; R L Panek; T C Major; B Olsewski; M J Ryan; T Dahring; G H Lu; J Keiser; A Amar; C Shen; A J Kraker; V Slintak; J M Nelson; D W Fry; L Bradford; H Hallak; A M Doherty
Journal:  J Med Chem       Date:  1997-07-18       Impact factor: 7.446

9.  Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

Authors:  David Wisniewski; Caryl L Lambek; Chongyuan Liu; Annabel Strife; Darren R Veach; Bhushan Nagar; Matthew A Young; Thomas Schindler; William G Bornmann; Joseph R Bertino; John Kuriyan; Bayard Clarkson
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

View more
  15 in total

1.  Photocleavable peptide-oligonucleotide conjugates for protein kinase assays by MALDI-TOF MS.

Authors:  Guangchang Zhou; Faraz Khan; Qing Dai; Juliesta E Sylvester; Stephen J Kron
Journal:  Mol Biosyst       Date:  2012-07-06

2.  Metabolism of peptide reporters in cell lysates and single cells.

Authors:  Angela Proctor; Qunzhao Wang; David S Lawrence; Nancy L Allbritton
Journal:  Analyst       Date:  2012-02-07       Impact factor: 4.616

Review 3.  Peptide reporters of kinase activity in whole cell lysates.

Authors:  Ding Wu; Juliesta E Sylvester; Laurie L Parker; Guangchang Zhou; Stephen J Kron
Journal:  Biopolymers       Date:  2010       Impact factor: 2.505

4.  A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.

Authors:  Juliesta E Sylvester; Stephen J Kron
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

5.  Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS.

Authors:  Guangchang Zhou; Xiaoliang Yan; Ding Wu; Stephen J Kron
Journal:  Bioconjug Chem       Date:  2010-10-20       Impact factor: 4.774

6.  Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads.

Authors:  Gargi Ghosh; Xiaoliang Yan; Stephen J Kron; Sean P Palecek
Journal:  Assay Drug Dev Technol       Date:  2012-09-20       Impact factor: 1.738

7.  Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts.

Authors:  Michael R Mand; Ding Wu; Darren R Veach; Stephen J Kron
Journal:  J Biomol Screen       Date:  2010-03-17

8.  Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.

Authors:  Cong Fang; Yanju Wang; Nam T Vu; Wei-Yu Lin; Yao-Te Hsieh; Liudmilla Rubbi; Michael E Phelps; Markus Müschen; Yong-Mi Kim; Arion F Chatziioannou; Hsian-Rong Tseng; Thomas G Graeber
Journal:  Cancer Res       Date:  2010-09-13       Impact factor: 12.701

9.  A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition.

Authors:  Andrew M Lipchik; Renee L Killins; Robert L Geahlen; Laurie L Parker
Journal:  Biochemistry       Date:  2012-09-12       Impact factor: 3.162

10.  (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

Authors:  Mikhail Doubrovin; Tatiana Kochetkova; Elmer Santos; Darren R Veach; Peter Smith-Jones; Nagavarakishore Pillarsetty; Julius Balatoni; William Bornmann; Juri Gelovani; Steven M Larson
Journal:  J Nucl Med       Date:  2010-01       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.